Immunofluorescence of AIF1/IBA1-FLAG transfected COS-7 cells using chicken α-AIF1/IBA1 (green) and mouse α-flag tag (red). Yellow/orange staining shows 100% correspondence between the two antibodies for recognition of transfected cells. Blue staining is DAPI and stains nuclei of both transfected and untransfected cells.
Bulk Order Anti-IBA1/AIF1 Antibody
AIF1, allograft inflammatory factor-1, (also known as Iba1, Ionized calcium binding adaptor molecule 1) is a 17 kDa protein that is a pro-inflammatory molecule that mediates calcium signals (Ito, D. et al 1998). During inflammation, increased expression of AIF1 occurs in microglia, macrophages, T-cells, synoviocytes, and adipocytes (Watano, K., et al, 2001). Expression of AIF-1 has been observed in healthy brains and varies throughout the day, gaining the highest expression in the prefrontal and parietal cortices when sleeping (Romcy-Pereira, R.N, et al, 2009). Increased expression of AIF1 has been observed in several diseases including breast cancer (Liu, S., et al 2008), atherosclerosis (Utans, U., et al, 1995), and rheumatoid arthritis (Kimura, M., et al, 2007).
Purified recombinant human full-length IBA1/AIF1 (Uniprot P55008) expressed in E.Coli
Human, Mouse, Rat
Store at 4°C in the dark. Under these conditions, the antibodies should have a shelf life of at least twelve months, provided they remain sterile. For longer term storage, aliquot and freeze to avoid freeze-thaw of the antibody.
Eggs from hens hyperimmunized with target were used to prepare an IgY fraction which was then subjected to antigen-specific affinity purification
Phosphate-buffered (10 mM) isotonic (0.9%, w/v) saline (“PBS," pH 7.2) with sodium azide (0.02%, w/v) added as a preservative.
Each new lot of this antibody is tested to confirm that it recognizes a single immunoreactive band of expected molecular weight when used to probe brain lysate.
These antibodies are to be used as research laboratory reagents and are not for use as diagnostic or therapeutic reagents in humans.
Carpenter, J.M., et al. 2022. Evaluation of Delayed LNFPIII Treatment Initiation Protocol on Improving Long-Term Behavioral and Neuroinflammatory Pathology in a Mouse Model of Gulf War Illness. Brain, Behavior, & Immunity, 100553.